Codexis 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Codexis reported 3rd quarter 2026 revenue of $19.3 million, compared with $8.6 million in the 3rd quarter 2025, and net loss of $8.1 million, compared with a loss of $19.6 million.
- Product gross margin was 74.5% for the 3rd quarter of 2026; research and development expenses were $12.6 million, and selling, general, and administrative expenses were $10.1 million.
- Codexis ended the 3rd quarter of 2026 with $72.7 million in cash, cash equivalents, and short-term investments, compared with $78.2 million at the end of 2025.
- The company raised approximately $25 million net of expenses through an equity financing during the 3rd quarter and subsequently entered into a $60 million senior secured term loan agreement, drawing down $42.5 million to pay off existing debt of $42 million.
- Pharma biocatalysis product sales for the first 9 months of 2026 increased 78.5% over the similar period last year, led by CDX 049; the business has 12 programs in Phase 2 or 3 clinical development and data readouts expected on 7 clinical trials in the next 2 years.
- Codexis reported producing multiple EcoSynthesis batches at 100-gram scale with high quality and reducing cycle times by 40%; at TIDES Europe, the company also reported 3 to 4-fold greater potency for stereo-defined siRNAs than the chemically synthesized stereorandom control, with comparable maximum gene knockdown.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this conference is being recorded. Now, I'll turn the conference over to Georgia Erbez, Chief Financial Officer and Chief Business Officer with Codexis.
Please go ahead. Thank you, operator.
With me today are Alison Moore, President and Chief Executive Officer, Stefan Lutz, Chief Scientific Officer, and Britton Jimenez, Senior Vice President, Sales and Marketing. During this call, management will make a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2026 revenue, anticipated milestones and product launches, facility expansions, technical milestones, and public announcements related thereto, as well as our strategies and prospects for revenue growth and successful execution of current and future programs and partnerships. To the extent these statements contained in the call are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the beliefs and expectations of management as of the statement date, November 12, 2026.
You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors that are, in some cases, beyond Codexis' control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis' filings with the Securities and Exchange Commission. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Now, I'll turn the call over to Alison.
Thank you, Georgia, and thanks, everyone, for joining the call. Codexis generates manufacturing solutions using highly engineered enzymes. The use of biocatalysis in the pharmaceutical industry has dramatically advanced the production of complex small molecule therapeutics, and we are now focused on delivering a significantly improved enzymatic production system to manufacture oligonucleotide medicine. As we enter the final quarter of 2026, I am very proud of our accomplishments so far. Today, we reported solid third quarter results with revenues of $19.3 million, our fourth consecutive quarterly on-target performance. Early in the quarter, we completed an equity offering in which we raised $25 million of net proceeds. In addition, this week, we announced we entered into a $60 million term loan agreement, of which $42.5 million was used in an initial drawdown to replace an existing loan.
This combination of strong operating performance, bolstering our cash balance, and deferring our debt repayment has strengthened our financial position as we complete the year. Georgia Erbez will give us more details on our financial achievements later in the call. 2026 has been a year of recognition for the developers of RNAi medicines, recognition of the huge therapeutic opportunity in large population indications, and also recognition that traditional manufacturing methods are insufficient to support the commercial aspirations of these important new medicines. Exploration of enzymatic approaches is building significantly, and Codexis' ECO Synthesis platform is in the lead in defining alternative approaches. Industry dialogue has shifted from proof of concept towards implementation of novel technologies into development pipelines. in October, we signed a feasibility study with a pioneer in the field to test ECO Synthesis fragments with stereochemical control.
In addition, we have signed an agreement with a large biopharmaceutical company to explore ligation of a clinical asset, and we are working on how to initiate a pilot-scale technology transfer of ECO Synthesis technology into their pilot plant in order for them to assess the production capability in-house. An important aspect of adoption readiness is the progress we've made to industrialize our platform. This includes scaling ECO Synthesis, improving operating parameters such as cycle time, and ensuring that we can meet product quality expectations. In Q3, we have produced multiple batches of material using ECO Synthesis at 100-gram scale and with high quality. During our process optimization, we have also reduced our cycle times by 40%. We will continue to optimize both scale and process performance toward kilo-scale readiness.
Some of this data was shared just last week at the TIDES Europe conference, where we also included a first glimpse at the optimized biological activity achieved by a stereo control of the siRNA. I will now turn the call over to Stefan Lutz for more details on our most recent TIDES data and the additional findings we are planning to provide in the future.
Stefan? Thank you, Alison. We had an exciting and busy schedule at TIDES Europe in Amsterdam last week.
In two presentations, the Codexis team delivered critical updates addressing three key customer questions: scale, platform capability, and stereochemistry. Let me elaborate briefly. As Alison already mentioned, our main stage presentation formally announced the successful scale-up of the ECO Synthesis manufacturing platform to 100 grams. Equally important, we were able to share the excellent quality of oligonucleotide produced at that scale, exceeding industry expectations at this stage of development. In addition, the 100-gram synthesis demonstrated a strong predictive relationship between process and product performance across scale. We saw consistent product quality of oligonucleotides manufactured by ECO Synthesis at both the 100 milligram and 100-gram scales. This consistency validates our process understanding, which is foundational for faster, more predictable development.
It also gives us confidence in our ability to anticipate and optimize performance as we advance to larger scale. Building this level of process understanding takes time, and there are no shortcuts. Over the past three years, beginning with our first 1-gram oligonucleotide synthesis in the fall of 2023, we have systematically built, scaled, and refined the ECO Synthesis manufacturing platform. Today, we believe we have established a robust foundation for large-scale manufacturing. Next, we presented an important expansion of the ECO Synthesis platform, the direct incorporation of tissue-targeting molecules at the end of therapeutic oligonucleotides. ECO Synthesis can now attach these targeting molecules efficiently, quantitatively within the standard workflow. Given the importance of targeted delivery in today's siRNA therapeutics, this capability addresses a critical customer need and further strengthens the platform's value proposition.
Already operational in our ECO Innovation Lab, this capability moves us closer to a true end-to-end oligonucleotide synthesis solution, from the first nucleotide to the final tissue-targeting molecule. Finally, we shared an exciting update from our ongoing work to understand the potential biological value of phosphorothioate stereochemistry. Two fully stereo-controlled antisense strands produced using ECO Synthesis were converted into therapeutic siRNA duplexes and tested in primary human hepatocytes. Compared with the chemically synthesized stereo-random control, the stereo-defined siRNAs showed three to four-fold greater potency while achieving comparable levels of maximum gene knockdown. Greater potency can translate into meaningful therapeutic and economic benefits, including the potential for lower doses, reduced manufacturing requirements and costs, less frequent administration, and potentially additional routes of administration. These early results provided encouraging evidence that stereochemical control could become an important source of therapeutic differentiation and value.
Our innovations presented at TIDES are generating significant industry interest and have led to the additional engagement with prospective customers and strategic partners. Importantly, the dialogue is shifting from questions about technical feasibility to considerations around deployment, regulatory strategy, and process economics. We see this as an indicator of growing confidence in the ECO Synthesis technology and a more mature focus on its path toward pipeline adoption. With that, I will turn the call over to Britton for an update on our broader commercial activities.
Britton. Thanks, Stefan. As our engagement with leading innovators progress, we are seeing interest in the value our ECO Synthesis platform can bring to customers.
In October, we announced a feasibility study with a pioneer in the field where Codexis will use our ECO Synthesis technology to synthesize stereo-defined fragments. This innovator uses a fragment synthesis and ligation strategy, but is seeking to increase the purity of fragment above what they can achieve using standard solid-phase chemistry techniques. They will be evaluating our platform as a way to achieve their manufacturing purity targets. Another example of innovator engagement is an evaluation agreement we signed this week with a leading biopharmaceutical company with a pipeline of siRNA assets. With this customer, we plan to assess ligation strategies for a late-stage asset and the performance of ECO Synthesis production at pilot scale.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
